Seres Therapeutics, Inc.
MCRB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 0.01 | -0.00 | 0.02 |
| FCF Yield | 1.30% | -13.87% | 22.06% | -30.45% |
| EV / EBITDA | -9.17 | -7.41 | -5.60 | -15.05 |
| Quality | ||||
| ROIC | -17.16% | -20.34% | -19.19% | -26.88% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.27 | 0.67 | 0.82 | 2.49 |
| Growth | ||||
| Revenue 3-Year CAGR | -85.96% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 116.32% | -150.12% | 168.96% | -11.96% |
| Safety | ||||
| Net Debt / EBITDA | -1.67 | -2.24 | -1.13 | -4.85 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 109.23 | -186.97 | -55.32 | -51.47 |